Amgen's Oncology Pipeline Data Highlighted at Upcoming Scientific MeetingTHOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 3, 2008 - Amgen (NASDAQ: AMGN) today announced that results from several preclinical and clinical trials investigating cancer treatment will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2008 in San Diego between April 12-16, 2008. Data will be presented on pipeline compounds: AMG 102, AMG 386, AMG 479, AMG 655 and motesanib diphosphate (AMG 706).
At AACR, Amgen will present data from studies investigating the tumor attacking potential of these products - alone or in combination with other therapies. These early studies have provided the biologic evidence to allow Amgen to launch a suite of exploratory Phase 1b/2 programs with these five molecules, across 15 tumor types with more than 30 clinical trials currently underway or planned.
"These data underscore our ongoing exploration of key biological processes that influence the growth of cancer cells including angiogenesis, apoptosis and growth regulation," said David Chang, M.D., vice president, Global Oncology Development at Amgen. "In addition, Amgen is actively pursuing identification of biomarkers that will help the company make better and earlier decisions about pipeline compounds, and enable targeted application of specific therapies to the patients who are more likely to benefit from treatment with them."
Selected Presentations of Interest
A program focused on the development of molecules that will interdict the abnormal process of new blood vessel formation. -0-
-- Combined treatment of angiopoietin and VEGF pathway antagonists enhances antitumor activity in preclinical models of colon carcinoma. Overview: Researchers combined AMG 386 with either bevacizumab or motesanib diphosphate (AMG 706) to explore inhibition of the VEGF/VEGFR pathways. Abstract No. 1113 (Sunday, April 13, 2008, 1:00 PM - 5:00 PM) -- In-vitro activity of motesanib diphosphate, an inhibitor of VEGFR, PDGFR and Kit tyrosine kinases, against imatinib-resistant Kit mutations. Overview: Researchers tested the activity of motesanib diphosphate (AMG 706) a small molecule inhibitor of VEGFR, PDGFR and Kit, against primary oncogenic and imatinib-resistant Kit mutations in Gleevec(R)-resistant gastrointestinal stromal tumors. Abstract No. 4887 (Tuesday, April 15, 2008, 1:00 PM - 5:00 PM) -- Modulation of radiation response by motesanib diphosphate in models of head and neck squamous cell (HNSCC) carcinoma. Overview: Researchers explored the benefit of adding AMG 706 to radiation therapy in HNSCC models. Abstract No. 5764 (Wednesday, April 16, 2008, 8:00 AM - 12:00 PM)
Cancer Cell Apoptosis
A program focused on the development of highly selective therapies to induce cancer cell death (apoptosis). -0-
-- Positron emission tomography (PET) measurement of death receptor 5 (DR5) receptor occupancy (RO) using (64)Cu-labeled AMG 655 in colo205 xenografts. Overview: Researchers evaluated the potential for PET to measure DR5 RO non-invasively using (64)Cu-labeled AMG 655 in an AMG 655- sensitive xenograft model (Colo205). Abstract No. 3162 (Monday, April 14, 2008, 1:00 PM - 5:00 PM) -- AMG 655, a monoclonal antibody agonist directed against Death Receptor 5, induces apoptosis in human colon carcinoma cell lines and its therapeutic potential is enhanced in combination with chemotherapeutic agents. Overview: Researchers evaluated the anti-tumor potential of AMG 655 when it is combined with irinotecan or 5-flurouracil in a colon cancer model. Abstract No. 1326 (Sunday, April 13, 2008, 1:00 PM - 5:00 PM) -- AMG 655, a fully human agonistic antibody against Death Receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. Overview: Researchers evaluated the anti-tumor potential of AMG 655 when it is added to gemcitabine in a pancreatic cancer model. Abstract No. 3999 (Tuesday, April 15, 2008, 8:00 AM - 12:00 PM)
A program focused on targeting cellular pathways that regulate cell pre-production, survival, migration and invasion which cancer cells often escape. -0-
-- Exploratory biomarkers in the HGF/SF: c-Met axis: preclinical and clinical results. Overview: Examination of exploratory biomarkers that may help determine treatment response in several types of cancers. Abstract No. 2804 (Monday, April 14, 2008, 1:00 PM - 5:00 PM) -- AMG 479, a fully human anti-IGF-1R monoclonal antibody, inhibits IGF-1 induced phospho-Akt and enhances the antineoplastic activity of cyclophosphamide in vivo Overview: Examining pathway activation in ongoing Ewing's sarcoma trial. Abstract No. 4001 (Tuesday, April 15, 2008, 8:00 AM - 12:00 PM) -- Domain-specific mechanisms of receptor inhibition by AMG 479, a fully-human IGF1R targeted antibody Overview: Inhibition of tumor growth with AMG 479 and other L2 domain antibodies versus CR and FnIII-1 antibodies in vivo using two different tumor models. Abstract No. 3994 (Tuesday, April 15, 2008, 8:00 AM - 12:00 PM)
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
This news release contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of April 3, 2008 and expressly disclaims any duty to update information contained in this news release.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.
In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.
The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates. Only the FDA can determine whether the product candidates are safe and effective for the use(s) being investigated. Further, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the FDA for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.
Amgen, Thousand Oaks
Christine Regan, 805-447-5476 (media)
Arvind Sood, 805-447-1060 (investors)
Posted: April 2008